Research programme: kinase inhibitors - Hanmi Pharmaceutical
Alternative Names: HM 571B; HM 60781Latest Information Update: 28 May 2018
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Cancer in South Korea
- 26 Feb 2007 Preclinical trials in Cancer in South Korea (unspecified route)